A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacodynamics Effects of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacodynamics Effects of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs REGN 2477 (Primary) ; Trevogrumab (Primary)
  • Indications Muscular disorders
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 17 Nov 2017 Planned End Date changed from 22 Feb 2018 to 1 Nov 2018.
    • 17 Nov 2017 Planned primary completion date changed from 22 Feb 2018 to 1 Nov 2018.
    • 15 Nov 2017 Planned End Date changed from 5 Oct 2018 to 22 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top